These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 4156144)

  • 41. [Long-term treatment of schizophrenic patients with leponex (clozapine)].
    Panteleeva GP; Tsutsul'kovskaia MIa; Mazurskiĭ MB; Danilenko IuM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(8):1247-56. PubMed ID: 696118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia".
    Chang YC; Lane HY
    J Clin Psychopharmacol; 2009 Aug; 29(4):391. PubMed ID: 19593183
    [No Abstract]   [Full Text] [Related]  

  • 43. [Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia].
    Cassan P
    Ann Med Psychol (Paris); 1985 Jul; 143(7):677-82. PubMed ID: 2870674
    [No Abstract]   [Full Text] [Related]  

  • 44. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 46. Test-retest performance in chronic schizophrenia on the Verdun Conditioning Program.
    Ananth JV; Ban TA; Lehmann HE
    Can Psychiatr Assoc J; 1972; 17(2):Suppl 2:SS227. PubMed ID: 5042902
    [No Abstract]   [Full Text] [Related]  

  • 47. [Aging of schizophrenics. Psycho-clinical study based on the Rorschach and Szondi tests].
    Melon J; Lebas A; Lieutenant L
    Acta Psychiatr Belg; 1973 Jan; 73(1):155-84. PubMed ID: 4599574
    [No Abstract]   [Full Text] [Related]  

  • 48. Specific indications for different classes of phenothiazines.
    Hollister LE; Overall JE; Kimbell I; Pokorny A
    Arch Gen Psychiatry; 1974 Jan; 30(1):94-9. PubMed ID: 4148660
    [No Abstract]   [Full Text] [Related]  

  • 49. [Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients].
    Lydecken K
    Schweiz Arch Neurol Neurochir Psychiatr; 1977; 120(1):75-82. PubMed ID: 323966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pimozide and piportil in the treatment of chronic schizophrenia (preliminary communication)].
    Masiak M; Majczak A; Hascewicz-Rzecka M; Kowalczyk A
    Psychiatr Pol; 1976; 10(6):655-60. PubMed ID: 13443
    [No Abstract]   [Full Text] [Related]  

  • 51. The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol.
    Carney MW; Sheffield BF
    Curr Med Res Opin; 1973; 1(7):423-6. PubMed ID: 4203952
    [No Abstract]   [Full Text] [Related]  

  • 52. Psychiatric pharmacotherapy and the schizophrenic defect.
    Molcan J; Floreánová L; Novotný V; Polák L; Rakús A; Motýlová A
    Act Nerv Super (Praha); 1973 May; 15(2):91. PubMed ID: 4148088
    [No Abstract]   [Full Text] [Related]  

  • 53. [Treatment of schizophrenic psychoses with Lyorodin].
    Schulz HD; Kluge HH; Korda W; Kube B
    Psychiatr Neurol Med Psychol (Leipz); 1977 Jun; 29(6):360-6. PubMed ID: 918199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Psychopathometric study of the prognostic significance of psychopathologic findings and premorbid personality for discharge of neuroleptic treated patients with schizophrenic psychoses].
    Möller HJ; von Zerssen D
    Nervenarzt; 1985 Sep; 56(9):498-505. PubMed ID: 2867479
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical differences among phenothiazines in schizophrenics. Introduction: specific indications for antipsychotics: elusive end of the rainbow.
    Hollister LE
    Adv Biochem Psychopharmacol; 1974; 9(0):667-73. PubMed ID: 4151921
    [No Abstract]   [Full Text] [Related]  

  • 56. Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study.
    Ortiz BB; Araújo Filho GM; Araripe Neto AG; Medeiros D; Bressan RA
    Braz J Psychiatry; 2013; 35(4):432-4. PubMed ID: 24402218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A word association measure of severity of current symptoms in schizophrenia.
    De Wolfe AS
    J Clin Psychol; 1973 Jan; 29(1):11-4. PubMed ID: 4405163
    [No Abstract]   [Full Text] [Related]  

  • 58. Loxapine succinate in the treatment of chronic schizophrenia.
    Nair NP; Decker BL; Schwartz G
    Curr Ther Res Clin Exp; 1976 Dec; 20(6):802-9. PubMed ID: 12919
    [No Abstract]   [Full Text] [Related]  

  • 59. Pipotiazine palmitate: a new depot neuroleptic.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):276-80. PubMed ID: 236151
    [No Abstract]   [Full Text] [Related]  

  • 60. Lithium-responsive schizophrenia: case reports.
    Prakash R
    J Clin Psychiatry; 1985 Apr; 46(4):141-2. PubMed ID: 3980453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.